ATE498620T1 - 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebs - Google Patents
4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebsInfo
- Publication number
- ATE498620T1 ATE498620T1 AT07865924T AT07865924T ATE498620T1 AT E498620 T1 ATE498620 T1 AT E498620T1 AT 07865924 T AT07865924 T AT 07865924T AT 07865924 T AT07865924 T AT 07865924T AT E498620 T1 ATE498620 T1 AT E498620T1
- Authority
- AT
- Austria
- Prior art keywords
- methylpyridine
- prodrugs
- carboxamide
- carbamoyl
- hydroxymethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87583006P | 2006-12-20 | 2006-12-20 | |
US98677307P | 2007-11-09 | 2007-11-09 | |
PCT/US2007/088365 WO2008079968A1 (en) | 2006-12-20 | 2007-12-20 | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE498620T1 true ATE498620T1 (de) | 2011-03-15 |
Family
ID=39247683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07865924T ATE498620T1 (de) | 2006-12-20 | 2007-12-20 | 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebs |
Country Status (12)
Country | Link |
---|---|
US (1) | US8101773B2 (de) |
EP (1) | EP2111401B1 (de) |
JP (1) | JP2010514691A (de) |
CN (1) | CN101679362A (de) |
AT (1) | ATE498620T1 (de) |
AU (1) | AU2007336873A1 (de) |
CA (1) | CA2673041A1 (de) |
DE (1) | DE602007012589D1 (de) |
DK (1) | DK2111401T3 (de) |
IL (1) | IL199403A0 (de) |
MX (1) | MX2009006579A (de) |
WO (1) | WO2008079968A1 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
PT1636585E (pt) | 2003-05-20 | 2008-03-27 | Bayer Pharmaceuticals Corp | Diarilureias com actividade inibidora de cinase |
JP4777887B2 (ja) | 2003-07-23 | 2011-09-21 | バイエル、ファーマシューテイカルズ、コーポレイション | 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素 |
NZ553804A (en) * | 2004-09-29 | 2010-07-30 | Bayer Schering Pharma Ag | Thermodynamically stable form of bay 43-9006 tosylate |
EP1868579B1 (de) | 2005-03-07 | 2010-09-29 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
CN102140093A (zh) * | 2010-02-03 | 2011-08-03 | 上海源力生物技术有限公司 | 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用 |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2637829T3 (es) * | 2012-06-15 | 2017-10-17 | Basf Se | Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CN105012321A (zh) * | 2015-08-20 | 2015-11-04 | 中国人民解放军第三军医大学第三附属医院 | 替加环素在制备抗胶质瘤药物中的应用 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3435977A4 (de) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | Pharmazeutische steroidhormonzusammensetzung |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
CN113662938B (zh) * | 2021-09-26 | 2022-08-16 | 广西科技大学 | 一种胺类衍生物在制备抗肿瘤药物组合物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1751139B1 (de) * | 2004-04-30 | 2011-07-27 | Bayer HealthCare LLC | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
DE102005015253A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
US20110195110A1 (en) * | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
-
2007
- 2007-12-20 JP JP2009543220A patent/JP2010514691A/ja active Pending
- 2007-12-20 MX MX2009006579A patent/MX2009006579A/es not_active Application Discontinuation
- 2007-12-20 AT AT07865924T patent/ATE498620T1/de active
- 2007-12-20 DK DK07865924.0T patent/DK2111401T3/da active
- 2007-12-20 WO PCT/US2007/088365 patent/WO2008079968A1/en active Application Filing
- 2007-12-20 CN CN200780051553A patent/CN101679362A/zh active Pending
- 2007-12-20 DE DE602007012589T patent/DE602007012589D1/de active Active
- 2007-12-20 CA CA002673041A patent/CA2673041A1/en not_active Abandoned
- 2007-12-20 US US12/520,609 patent/US8101773B2/en not_active Expired - Fee Related
- 2007-12-20 EP EP07865924A patent/EP2111401B1/de not_active Not-in-force
- 2007-12-20 AU AU2007336873A patent/AU2007336873A1/en not_active Abandoned
-
2009
- 2009-06-17 IL IL199403A patent/IL199403A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20100063107A1 (en) | 2010-03-11 |
US8101773B2 (en) | 2012-01-24 |
CN101679362A (zh) | 2010-03-24 |
DK2111401T3 (da) | 2011-05-30 |
CA2673041A1 (en) | 2008-07-03 |
DE602007012589D1 (de) | 2011-03-31 |
EP2111401A1 (de) | 2009-10-28 |
AU2007336873A1 (en) | 2008-07-03 |
WO2008079968A1 (en) | 2008-07-03 |
IL199403A0 (en) | 2010-03-28 |
MX2009006579A (es) | 2009-07-22 |
JP2010514691A (ja) | 2010-05-06 |
EP2111401B1 (de) | 2011-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE498620T1 (de) | 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebs | |
NO2023022I1 (no) | cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate | |
DK2029547T3 (da) | FXR-agonister | |
TN2009000291A1 (en) | Inhibitors of mek | |
ATE528286T1 (de) | 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs | |
NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
DK1836201T4 (da) | Pyrrolidininhibitorer af IAP. | |
DK2054418T3 (da) | Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer | |
EA200870569A1 (ru) | Соединения и способы модуляции fxr | |
CY1113386T1 (el) | Αναστολεις πρωτεασωματος | |
CY1112117T1 (el) | Υδροξυλιωμενες και μεθοξυλιωμενες κυκλοπεντα[d]πυριμιδινες ως αναστολεις ακτ πρωτεϊνικης κινασης | |
ECSP066886A (es) | Compuestos y métodos para el tratamiento de dislipidemia | |
ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
DK1937639T3 (da) | Pyridinaminosulfonyl-substituerede benzamider som inhibitorer af cytochrom P450 3A4 (CYP3A4) | |
EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
ATE522509T1 (de) | Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase | |
EA201100035A1 (ru) | Производные тиазолилпиперидина | |
EA201000633A1 (ru) | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ | |
MX2010002938A (es) | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. | |
DK1893213T3 (da) | Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme | |
WO2008011539A3 (en) | Anesthetic compounds | |
CL2009001494A1 (es) | Compuestos derivados de n-((5s)-3-(4-(3-pirrolidin-1-il)fenil)-2-oxo-5-oxazolidinmetil)acetamida; procedimiento para prepararlos; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas. | |
ZA200904658B (en) | 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl) phenyl]-1H-pyrazol-5-yl} carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer | |
EA201990219A2 (ru) | Ингибиторы mek и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 2111401 Country of ref document: EP |